6838 Stock Overview
Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan.
Formosa Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$35.70|
|52 Week High||NT$61.00|
|52 Week Low||NT$29.00|
|1 Month Change||-16.98%|
|3 Month Change||-20.67%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-36.25%|
Recent News & Updates
|6838||TW Pharmaceuticals||TW Market|
Return vs Industry: Insufficient data to determine how 6838 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 6838 performed against the TW Market.
|6838 Average Weekly Movement||7.3%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 6838 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 6838's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007, an aqueous-based ophthalmic nanosuspension that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002, a topical antibiotic for infectious eye diseases, such as blepharitis; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer, as well as lung fibrosis.
Formosa Pharmaceuticals Fundamentals Summary
|6838 fundamental statistics|
Is 6838 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6838 income statement (TTM)|
|Cost of Revenue||NT$267.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-4.06|
|Net Profit Margin||-1,405.18%|
How did 6838 perform over the long term?See historical performance and comparison
Is Formosa Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6838's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6838's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6838 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.
PE vs Market: 6838 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6838's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6838 is overvalued based on its PB Ratio (9x) compared to the TW Pharmaceuticals industry average (2x).
How is Formosa Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Formosa Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Formosa Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 6838 is currently unprofitable.
Growing Profit Margin: 6838 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6838's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6838's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6838 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).
Return on Equity
High ROE: 6838 has a negative Return on Equity (-101.93%), as it is currently unprofitable.
How is Formosa Pharmaceuticals's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6838's short term assets (NT$234.5M) exceed its short term liabilities (NT$19.3M).
Long Term Liabilities: 6838's short term assets (NT$234.5M) do not cover its long term liabilities (NT$276.2M).
Debt to Equity History and Analysis
Debt Level: 6838 is debt free.
Reducing Debt: 6838 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6838 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 6838 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.1% each year
What is Formosa Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6838's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6838's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6838's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6838's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6838 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Erick Co serves as Director of New Drug Development at ScinoPharm Taiwan, Ltd. Dr. Erick Co is Chief Executive Officer of Formosa Pharmaceuticals, Inc. Dr. Erick Co served as Senior Scientist at Exelix...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: 6838 only recently listed within the past 12 months.
Formosa Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Formosa Pharmaceuticals, Inc.
- Ticker: 6838
- Exchange: TPEX
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$3.528b
- Shares outstanding: 98.83m
- Website: https://www.formosapharma.com
Number of Employees
- Formosa Pharmaceuticals, Inc.
- No. 57, Fuxing North Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.